In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Eurothrombosis 2018

A report from the ESC Working Group on Thrombosis, by Dr Gemma Chiva-Blanch and Dr William Parker

The ESC Working Group on Thrombosis celebrated its biannual meeting Eurothrombosis 2018 on October 4th - 6th in Barcelona. It was an outstanding and exciting meeting with almost 250 attendees from 36 countries. The meeting included the Young Investigators Award Session, aimed at recognizing the achievements of young scientists working in the field of Thrombosis. Six exceptional presentations were given, resulting in 3 young researchers awarded. On behalf of the Young Thrombosis Group (YTRG), we want to congratulate them through this small tribute.

Miriam Sjastad Langseth.jpgMiriam Sjåstad Langseth, MD, is a PhD candidate under the supervision of Prof. Ingebjørg Seljeflot, currently working at the Centre for Clinical Heart Research, Ullevål University Hospital, Oslo, Norway, since January 2017. Miriam does translational research in Cardiology, and her PhD project is related to neutrophil extracellular traps (NETs) in coronary artery disease (CAD). In this framework, Miriam investigated whether circulating markers of NETs were associated with clinical outcomes and coagulability in 956 STEMI patients. She observed that patients with above-median dsDNA levels had elevated concentrations of D-dimer and prothrombin fragment 1+2, and they were also at increased risk of death in the long term. Her results suggest an involvement of NETs in CAD progression, although she concludes that the prognostic relevance of NETs markers deserves further exploration.

Temo Barwari.jpgTemo Barwari, MD, PhD, recently completed a PhD under the supervision of Professor Manuel Mayr at King’s College, London, UK, and is currently an Internal Medicine Resident at the Flevoziekenhuis, Almere, the Netherlands. He presented his work on the role of microRNA-21 (miR-21), which has known profibrotic properties, in regulating platelet function. Temo showed that whilst altering levels of miR-21 had only limited effects on extracellular matrix protein secretion from cardiac fibroblasts, miR-21 levels correlated with platelet-derived profibrotic factors, including tumour growth factor β1 (TGF-β1), in a human cohort. He identified Wiskott-Aldrich syndrome protein as the direct target of miR-21 and showed that platelet release of TGF-β1 was reduced, in mice, by antagomiR-21. Temo concluded that these effects may contribute to the antifibrotic effects of miR-21 inhibitors.

Wael Sumaya.jpgWael Sumaya, MD, PhD, is Clinical Lecturer in Cardiology at the University of Sheffield, UK. He works under the supervision of Professor Rob Storey (Sheffield) and Dr Ramzi Ajjan (Leeds, UK). His research focuses on the relationship between parameters of acellular coagulation and outcomes after acute coronary syndrome (ACS). Wael presented his research on fibrin clot dynamics, measured in samples taken from 4354 patients participating in the PLATelet inhibition and patient Outcomes (PLATO) study. He found that higher fibrin clot lysis time was significantly associated with poorer clinical outcomes after ACS, a relationship that persisted after adjustment for other risk factors, and regardless of the assigned P2Y12 inhibitor. In the next phase of his research, Wael hopes to explore new targeted strategies for correcting hypofibrinolysis.